Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: steve kammerer who wrote (10312)	2/24/2011 10:39:11 AM
From: Arthur Radley	Respond to of 10345

(IMO) Not very much! This is the norm now for many pharmas--outsourcing their development projects to this type company that has the ability to conduct data collection in foreign countries. Merely look at the major reduction in force by the likes of Pfizer where they are cutting their scientific staff in huge numbers. As for Elan, first they have to have projects and at the moment they don't have what I call a robust pipeline. Near term, all they have is a hope with Tysbari and the Alz. project that is in Phase III........based on earlier results......I don't hold out much hope for that project.